Similar articles

• Low-density lipoprotein level on admission is not associated with postintravenous thrombolysis intracranial hemorrhage in patients with acute ischemic stroke.

  Hong CT, Chiu WT, Chi NF, Lai LY, Hu CJ, Hu HH, Chan L. Hong CT, et al. J Investig Med. 2019 Mar;67(3):659-662. doi: 10.1136/jim-2018-000827. Epub 2018 Oct 26. J Investig Med. 2019. PMID: 30367009
• The iScore predicts efficacy and risk of bleeding in the National Institute of Neurological disorders and Stroke Tissue Plasminogen Activator Stroke Trial.

  Saposnik G, Demchuk A, Tu JV, Johnston SC; Stroke Outcomes Research Canada (SORCan) Working Group. Saposnik G, et al. J Stroke Cerebrovasc Dis. 2013 Aug;22(6):876-82. doi: 10.1016/j.jstrokecerebrovasdis.2012.09.001. Epub 2012 Oct 24. J Stroke Cerebrovasc Dis. 2013. PMID: 23102741 Clinical Trial.
• Thrombolysis is an Independent Risk Factor for Poor Outcome After Carotid Revascularization.

  Vellimana AK, Washington CW, Yarbrough CK, Pilgram TK, Hoh BL, Derdeyn CP, Zipfel GJ. Vellimana AK, et al. Neurosurgery. 2018 Nov 1;83(5):922-930. doi: 10.1093/neuros/nyx551. Neurosurgery. 2018. PMID: 29136204 Free PMC article.
• Not all clots are created equal: a review of deficient thrombolysis with tissue plasminogen activator (tPA) in patients with metabolic syndrome.

  Mosimah CI, Murray PJ, Simpkins JW. Mosimah CI, et al. Int J Neurosci. 2019 Jun;129(6):612-618. doi: 10.1080/00207454.2018.1550400. Epub 2018 Dec 27. Int J Neurosci. 2019. PMID: 30465701 Free PMC article. Review.
• How can we improve stroke thrombolysis rates? A review of health system factors and approaches associated with thrombolysis administration rates in acute stroke care.

  Paul CL, Ryan A, Rose S, Attia JR, Kerr E, Koller C, Levi CR. Paul CL, et al. Implement Sci. 2016 Apr 8;11:51. doi: 10.1186/s13012-016-0414-6. Implement Sci. 2016. PMID: 27059183 Free PMC article. Review.